Register Login

Nuvalent Inc (NUVL)

(10% Negative) Nuvalent Inc (NUVL) Announces Delay in adult patients Trials for clinically proven kinase targets in cancer Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 7:04 p.m.

    📋 Nuvalent Inc (NUVL) - Clinical Trial Update

    Filing Date: 2026-01-14

    Accepted: 2026-01-14 06:30:30

    Event Type: Clinical Trial Update

    Event Details:

    Nuvalent Inc (NUVL) Announces Clinical Trial Update Nuvalent Inc (NUVL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: adult patients, TKI pre-treated patients
    • Diseases/Conditions: clinically proven kinase targets in cancer, advanced
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process, Regulatory Timeline
    • Collaboration: FDA
      • planned for the second half of 2026
      • planned for the first half of 2026
      • anticipated into 2029

    🔬 Clinical Development Pipeline (Nuvalent Inc):

    Product Type Development Stage Therapeutic Area Source
    NVL-330 DRUG Phase PHASE1 Locally Advanced Solid Tumor ClinicalTrials.gov
    NVL-655 DRUG Preclinical Non Small Cell Lung Cancer ClinicalTrials.gov
    NVL-520 DRUG Preclinical Non Small Cell Lung Cancer ClinicalTrials.gov
    Alectinib DRUG Phase PHASE3 Non-small Cell Lung Cancer ClinicalTrials.gov
    Neladalkib (NVL-655) DRUG Phase PHASE3 Non-small Cell Lung Cancer ClinicalTrials.gov
    Zidesamtinib (NVL-520) DRUG Phase PHASE1 Locally Advanced Solid Tumor ClinicalTrials.gov
    ePass DEVICE Approved Obesity ClinicalTrials.gov
    Endo Bypass System DEVICE Approved Obesity ClinicalTrials.gov
    ValenTx Endo Bypass System DEVICE Approved Obesity ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Nuvalent Inc
    • Ticker Symbol: NUVL

Search

News categories